Article

CMS to increase eye-code payments

Combining evaluation and management with eye-visit codes will result in a 2% increase in ophthalmology-related Medicare payments next year.

Washington, DC-The relinking of evaluation and management with eye-visit codes will result in a 2% increase in ophthalmology-related Medicare payments next year. This increase will help offset the plan by the Centers for Medicare and Medicaid Services (CMS) to cut the 2008 Medicare conversion factor by 10.1% under the sustainable growth rate (SGR) formula, which links Medicare reimbursement to the country's gross domestic product.

The 2008 Medicare Physician Fee Schedule was issued in November and is effective in January.

"Convincing the American Medical Association (AMA) Relative-value Update Committee (RUC) and CMS about the importance of increased eye-visit code payments is the result of 2 years of hard work that has paid off in the new rule. These increased payments more accurately reflect the value of the services provided by physicians," said Michael X. Repka, MD, secretary for federal affairs for the AAO.

CMS also continues to phase in new data on practice expenses; therefore, ophthalmologists face another 1% decrease in payments next year. The AAO has called on CMS to update data for all specialties and is working with the AMA to develop a new medicine-wide survey with the hopes of improving future payments related to ophthalmology.

Other changes that will be implemented with the new fee schedule:

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.